Case report

Early Onset Diabetes in Two Children due to Progeria, a Monogenic Disease of DNA Repair

Holder and Schwitzgebel Early Onset Diabetes in Children with Progeria

Martin Holder¹, Valerie Schwitzgebel²
¹Klinikum Stuttgart, Olgahospital, Department of Pediatric Endocrinology and -Diabetology, 70174 Stuttgart, Germany
²Hopital des Enfants, Endocrinologie et diabetologie pediatriques, 1211 Geneve, Switzerland

Abstract
Progeria Syndrome is a rare disorder in childhood which causes accelerated systemic aging. Due to the accelerated aging process, disorders which normally occur only in old age will appear in these children at a much younger age. We report two children with Progeria syndrome, in whom fulminant diabetes mellitus manifested at a very early age.

Keywords: Progeria syndrome – diabetes mellitus – metformin - prevention

Conflict of interest: The authors declare that they have no conflict of interest regarding these clinical reports.

Introduction
Progeria Syndrome is a group of very rare genetic disorders which are characterized by premature aging and classified into various names based on causative etiology: Hutchinson-Gilford progeria syndrome (HGPS), Néstor-Guillermo progeria syndrome (NGPS), atypical progeria syndromes (APSS), restrictive dermopathy (RD), mandibulocaudal dysplasia (MAD), Werner syndrome (WS), Bloom syndrome (BS), Rothmund-Thomson syndrome (RTS), Cockayne syndrome (CS), xeroderma pigmentosum (XP), trichothiodystrophy (TTD), Fanconi anemia (FA), Seckel syndrome (SS), ataxia telangiectasia (AT), ataxia telangiectasia-like disorder (ATLD), cerebrotendinal microangiopathy with calcifications and cysts (CRMCC), and Nijmegen breakage syndrome (NBN).

Children affected with progeria syndrome appear normal at birth, but the clinical manifestations become apparent in the first few years of life. Despite failure to thrive, dermatologic, musculoskeletal, and neurologic abnormalities; and eventually life-limiting cardiovascular disease can occur. Additionally they can have audiologic, dental, and ophthalmologic issues that impair their lives. Less is known about metabolic complications in children with progeria syndrome. In Werner syndrome, also known as adult progeroid syndrome, type 2 like diabetes mellitus is one of the clinical manifestations of the disease and attention must give to the differential diagnosis [1].

We report about two patients (a boy and a girl) with Progeria syndrome, in whom fulminant diabetes mellitus manifested at a very early age.

Case Reports
Case 1: Boy with Cockayne syndrome (CS)
The boy was born per section on the 38th week of pregnancy with a weight of 2.250 g (1 P., -2.42z), 41 cm length (< 1 P., -2.79z). Within the first year delayed motoric development, particularly of the gross motor skills and delayed linguistic development.

At the age of 22 months the boy was first seen in our social pediatric department due to severe psychomotoric retardation, gross motor skills and delayed linguistic development.

4.39z) and 31 cm head circumference (< 1 P., -2.79z). Within the first year delayed motoric development, particularly of the gross motor skills and delayed linguistic development.

The criteria for HHS include: Plasma glucose concentration > 600 mg/dl (33.3 mmol/L), venous pH > 7.25, arterial pH > 7.30, serum bicarbonate >15 mmol/L, small ketonuria, absent to mild ketonemia, effective serum osmolality >320 mosmol/kg and altered consciousness (e.g., obtunded, aggressive) or seizures.

At that time his weight was 8700 g (approx. 12 kg below the 3. P.), his length 86 cm (approx. 30 cm below the 3. P.) and hypertensive RR-values with 174/147 mm HG. The initial plasma glucose level was 925 mg/dl, pH 7.4, HbA1c 7.3% (56.28 mmol/mol), C-peptide 9 ng/ml and serum osmolality 345 mosmol/kg (275 – 305 mosmol/kg) (see table 1). As a result of high insulin sensitivity at that stage and to avoid rapid dropping in blood sugar with standardized insulin treatment and developing hypernatremia, the patient was managed on the intensive care unit with meticulous rehydration and a gradual, slow reduction in plasma glucose. There insulin was administered intravenously very carefully with 0.025 – 0.05 IE/ body weight / h. After emergency treatment and clinical recovery the blood glucose levels could be adequately controlled in relation to tube feeding using a rapid acting human insulin 3 x daily to the feedings and long acting insulin analogues, which could be stopped.

Conflict of interest: The authors declare that they have no conflict of interest regarding these clinical reports.

Conflict of interest: The authors declare that they have no conflict of interest regarding these clinical reports.
Hutchinson-Gilford progeria syndrome (HGPS)
The girl was already diagnosed externally with Hutchinson-Gilford progeria syndrome as she first presented to our department at the age of 14 years with severe coronary heart disease and hyporegenerative anemia requiring regular blood transfusions. The diagnosis of HGPS has not been genetically proven as the parents refused genetic tests. At first presentation her weight was 13.6 kg (26 kg below the 3.P.), her length 120 cm (31 cm below the 3.P.) and her RR-value 95/55 mm HG. She showed tachycardia with a pulse rate of 120 per minute and oxygen saturation of 92%. As part of the initial investigations she was found to have elevated blood glucose levels: Plasma glucose 324 mg/dl (18 mmol/l), HbA1c 8.6% (70.49 mmol/mol), C-Peptid 20.24 ng/ml and insulin 500 mU/l (see table 1). As the patient had already been receiving palliative care, a decision was made in conjunction with the parents that no further active treatment, neither insulin nor metformin, would be administered.
Both children have subsequently died. Their mortality was not related to diabetes.

Discussion
The two reported children had progeria syndrome due to different etiologies. The girl clinically had Hutchinson-Gilford progeria syndrome (HGPS) and the boy Cockayne syndrome. Both children developed partly fulminant type 2 diabetes mellitus, which is yet not known in these young patients. Only in Werner syndrome, the adult form of progeria syndrome, diabetes mellitus due to severe insulin resistance is known as possible clinical manifestations. The possible mechanism of insulin resistance includes reduced insulin receptors in fat cells, loss of signal transduction after the binding of normal insulin to normal receptors and defective post-receptor step [1]. In addition, dysregulation of adipocytokine may be another mechanism for the development of diabetes mellitus in Werner syndrome patients.

Hutchinson-Gilford progeria syndrome (HGPS) is due to a mutation in the LMNA gene that leads to the production of a truncated and toxic form of lamin A called progerin [3]. Progerin accumulates and triggers growth impairment, lipodystrophy, dermal and bone abnormalities and cardiovascular changes, leading to a shortened lifespan. There is a major rationale for targeting progerin at different levels. Attempts to develop treatment in HGPS associated with progerin accumulation may thus rely on a multi-approach combination, including its decreased production, increased degradation, or downstream noxious cascades [4].

In 2011, the RNA-binding protein SRSF1 (serine/arginine-rich splicing factor 1) was shown to affect alternative splicing of LMNA in human HGPS primary fibroblasts and mouse LMNA fibroblast [5]. A recent whole-genome transcription analysis has revealed that SRSF1 expression is regulated by the anti-diabetic drug metformin [6]. In a current study it could be demonstrated that metformin reduces progerin expression by regulating SRSF1 expression and altering the pathological phenotypes of HGPS cells. After treatment with 5 mmol/l of metformin a decrease in SRSF1 protein of up to 40% could be demonstrated [3]. Therefore, it may be interesting to explore the therapeutic potential of metformin in patients with progeria.

Laminopathies, due to mutations in LMNA, encoding A type-lamins, can lead to premature ageing but also to lipodystrophic syndromes, showing that these diseases may have related physiological mechanisms [10]. Lipodystrophy syndromes are frequently associated with hormonal and metabolic derangements resulting in severe comorbidities, that depend on the subtype, extent of fat loss, age and gender. Many complications of lipodystrophy are secondary to deficient adipose mass, resulting in ectopic lipid storage in the liver, muscle, and other organs and causing severe insulin resistance. Insulin resistance leads to diabetes, hypertriglyceridemia, polycystic ovarian syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD) [11].

The male patient had proven Cockayne syndrome resulting in a severe progeria syndrome. Only recently inherited defects in DNA repair have been identified as the underlying cause [12]. DNA maintenance is emerging as a central factor in a multitude of diseases and loss of genomic integrity leads to severe multimystem syndromes. Loss of transcription-coupled repair, which occurs with mutations in two hold excision repair of cross-complementing genes (ERCC6 and ERCC8) leads to the Cockayne syndrome which is characterized by progressive cachexia, severe growth retardation and leukoencephalopathy. Gradually our understanding of the clinical spectrum of the progeroid syndromes is becoming clearer. Clinical trials for treatment of these monogenic DNA-repair disorders may well be the key to intervention in other diseases associated with genomic damage and perhaps even for aging itself [12].

Due to the therapeutic potential of metformin children and adolescents with progeria syndrome should be screened for diabetes from a very early age on and treated with metformin. Metformin is a well-known anti-diabetic drug which has demonstrated a good safety profile in millions of patients over the past two decades. In children and adolescents with type 2 diabetes metformin is the recommended first line therapy and is superior to treatment with sulfonylureas [7,8]. Metformin acts through adenosine monophosphate (AMP) kinase in liver, muscle, and fat tissue, with a predominant action on the liver. Hepatic glucose output is reduced by decreased gluconeogenesis. Insulin stimulated glucose uptake is increased in muscle and fat. Long-term use is associated with a 1–2% reduction in Hba1c [8].

Recently, new pathways in addition to AMPK activation – as discussed above – were discovered, which would explain the additional positive properties of metformin [9]. The potential use of metformin as an anti-aging drug and its effect on progerin expression may be interesting to explore in the future.

Both children were unfortunately not treated with metformin. In the male patient we didn’t known at that time about the potential effects of metformin on both the metabolic and disease-progressive course. Treatment of the girl with metformin was refused by the patient and her family because of the palliative care status. But for further affected children with Progeria syndrome at risk of developing early type-2 like diabetes, treatment with metformin at an early stage should be recommended. As a result of, early symptoms of diabetes could be prevented and the clinical course of progeria potentially delayed.

Conclusion
Less is known about type 2 like diabetes mellitus in children and adolescents with progeria-syndrome although they have a high risk of developing diabetes mellitus. Therefore, early and regular screening for diabetes mellitus is mandatory. Treatment with metformin at an early stage should be recommended to prevent early symptoms of diabetes and potentially delay the clinical course of progeria.
Acknowledgments
I would like to thank Mary Morgan, MD for providing translation assistance.

References

Table 1. Main Characteristics of both patients with Progeria Syndrome

<table>
<thead>
<tr>
<th></th>
<th>Case 1</th>
<th>Case 2</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gender</td>
<td>male</td>
<td>female</td>
</tr>
<tr>
<td>Age at Diabetes Manifestation (years)</td>
<td>7</td>
<td>14</td>
</tr>
<tr>
<td>Initial Blood Sugar (mg/dl / mmol/l)</td>
<td>925 / 51.3</td>
<td>324 / 17.9</td>
</tr>
<tr>
<td>Initial HbA1c (%)</td>
<td>7.3</td>
<td>8.6</td>
</tr>
<tr>
<td>Initial C-Peptid (mg/dl)</td>
<td>9</td>
<td>20.24</td>
</tr>
<tr>
<td>Initial Serum Osmolarity (mosm/kg)</td>
<td>345</td>
<td>-</td>
</tr>
<tr>
<td>Initial Insulin (mU/l)</td>
<td>-</td>
<td>500</td>
</tr>
<tr>
<td>Type of Progeria Syndrome</td>
<td>Cockayne-Syndrome</td>
<td>Hutchinson-Gilford-Progeria-Syndrome (HGPS)</td>
</tr>
<tr>
<td>Additional disorders</td>
<td>Hepatopathy</td>
<td>Leukodystrophy</td>
</tr>
<tr>
<td></td>
<td>Leukodystrophy</td>
<td>Spastic Tetraparesis</td>
</tr>
<tr>
<td></td>
<td>Severe Coronary Heart Disease</td>
<td>Hyporegenerated Anemia</td>
</tr>
<tr>
<td>Age of death (years)</td>
<td>9</td>
<td>17</td>
</tr>
</tbody>
</table>